Inovio Pharmaceuticals Inc INO

Healthcare Biotechnology

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.

NDAQ:INO - Post by User

Inovio Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by 7Twiggyon Mar 04, 2021 10:09pm

201 Views

Post# 32725065

Here for three reasons

Flynin I am here for three reasons

- INO 4800 Covid work

- pipeline of other activites.

- Hartaj Singh recommendation of $35 which I think is low if 4800 a go.

Have sold a lot of these plays way too early. If it does't work out I will have a nice tax loss
If it does work out, it could make the positive results we are seeing with Moderna seem marginal.

<< Previous

Bullboard Posts

Next >>

Advancing an underexplored area of the Yukon with the same geology as B.C’.s Golden Triangle